Suggestions

Du même auteur

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy

Archive ouverte | Leconet, Wilhem | CCSD

International audience. AXL receptor tyrosine kinase (RTK) is implicated in proliferation and invasion of many cancers, particularly in pancreatic ductal adenocarcinoma (PDAC), for which new therapeutic options are ...

Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.: Anti-HER3 antibodies in cancer therapy

Archive ouverte | Lazrek, Yassamine | CCSD

International audience. Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to...

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

Archive ouverte | Thomas, Gaëlle | CCSD

International audience. The anti-HER2 antibody pertuzumab inhibits HER2 dimerization and affects HER2/ HER3 dimer formation and signaling. As HER3 and its ligand neuregulin are implicated in pancreatic tumorigenesis...

Chargement des enrichissements...